Who is sponsoring NCT06084091?

NCT06084091 is sponsored by Spectrocor.

What drugs are being tested in NCT06084091?

Interventions in NCT06084091: Myocardial spectrometric measurement.

What condition does NCT06084091 study?

NCT06084091 studies Coronary Artery Disease, Heart Valve Diseases.

Is NCT06084091 still recruiting?

NCT06084091 is currently status unknown. Last updated 25 October 2023.

Last reviewed 2023-10-25 · How we verify

NCT06084091: ECS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spectroscopic Assessment of Intramyocardial Oxygen Saturation During Open-Heart Surgery

Status unknown Last updated 25 October 2023

What this trial tests

trial testing Myocardial spectrometric measurement in Coronary Artery Disease in 40 participants. Status unknown.

Timeline

6 October 2023

Primary endpoint
30 November 2025

30 November 2025

Quick facts

Lead sponsor	Spectrocor
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	6 October 2023
Primary completion	30 November 2025
Estimated completion	30 November 2025
Sites	1 location across Finland

Drugs / interventions tested

Myocardial spectrometric measurement

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Heart Valve Diseases — all drugs for Heart Valve Diseases →

Sponsor

Spectrocor

Who can join

Adults 18 to 90, any sex, with Coronary Artery Disease or Heart Valve Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to test in the safety and performance of intraoperative myocardial spectroscopic measurement in open-heart surgery patients The main questions it aims to answer are: * The Devices can record myocardial spectrometric data for analysis, and * How these measures correlate with the occurring events, procedures, and clinical parameters during the operation. * Number of participants with device-related adverse events as assessed by CTCAE v4.0

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Spectrocor trials

Trials by the same sponsor.

NCT05479968 — Spectroscopic Assessment of Intramyocardial Oxygen Saturation Feasibility During Open-heart Surgery · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06084091 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spectrocor
Last refreshed: 25 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06084091.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing